Basel Medical Group Ltd (BMGL)

Basel Medical Group Income Statement

Financials in millions SGD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Revenue	11.32	10.05	9.7	10.66
Revenue Growth (YoY)	12.63%	3.60%	-8.98%	-
Cost of Revenue	-2.53	-2.25	-2.34	-2.18
Gross Profit	13.85	12.3	12.04	12.84
Selling, General & Admin	-9.87	-5.15	-4.85	-5.75
Depreciation & Amortization Expenses	-1.18	-0.53	-0.56	-0.58
Other Operating Expenses	11.15	-	-	-
Total Operating Expenses	0.09	-5.68	-5.41	-6.33
Operating Income	13.75	17.98	17.45	19.16
Interest Expense	-0.2	-0.18	-0.24	-0.32
Other Non-Operating Income (Expense)	1.1	0.46	0.41	0.55
Total Non-Operating Income (Expense)	0.9	0.28	0.17	0.23
Pretax Income	-12.51	2.4	2.13	2.39
Provision for Income Taxes	0.42	-0.33	-0.35	-0.41
Net Income	-24.18	4.15	1.78	2.79
Minority Interest in Earnings	0	-	-	-
Net Income to Common	-24.18	4.15	1.78	2.79
Net Income Growth	-	132.47%	-36.20%	-
Shares Outstanding (Basic)	19	16	16	16
Shares Outstanding (Diluted)	19	16	16	16
Shares Change (YoY)	15.60%	-	-	-
EPS (Basic)	-0.64	0.13	0.11	0.12
EPS (Diluted)	-0.64	0.13	0.11	0.12
EPS Growth	-	18.18%	-8.33%	-
Free Cash Flow	-4.4	2.5	2.59	2.59
Free Cash Flow Growth	-	-3.56%	-	-
Free Cash Flow Per Share	-0.23	0.15	0.16	0.16
Gross Margin	122.32%	122.37%	124.09%	120.44%
Operating Margin	121.49%	178.91%	179.82%	179.80%
Profit Margin	-213.57%	41.25%	18.38%	26.22%
FCF Margin	-38.86%	24.89%	26.74%	24.34%
EBITDA	14.93	18.51	18.05	19.77
EBITDA Margin	131.92%	184.17%	186.05%	185.47%
EBIT	13.75	17.98	17.45	19.16
EBIT Margin	121.49%	178.91%	179.82%	179.80%
Effective Tax Rate	-3.34%	-13.80%	-16.34%	-17.12%

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q